Etanercept with IVIg for acute Kawasaki disease: a long-term follow-up on the EATAK trial
Authors:
- 12 May 2022
- journal article
- research article
- Published by Cambridge University Press (CUP) in Cardiology in the Young
- Vol. 33 (4) , 613-618
Abstract
Background: The Etanercept as Adjunctive Treatment for Acute Kawasaki Disease, a phase-3 clinical trial, showed that etanercept reduced the prevalence of IVIg resistance in acute Kawasaki disease. In patients who presented with coronary artery involvement, it reduced the maximal size and short-term progression of coronary artery dilation. Following up with this patient group, we evaluated the potential long-term benefit of etanercept for coronary disease.Methods: Patients were followed for at least 1 year after the trial. The size of dilated arteries (z-score ≥ 2.5) was measured at each follow-up visit. The z-score and size change from baseline were evaluated at each visit and compared between patients who received etanercept versus placebo at the initial trial.Results: Forty patients who received etanercept (22) or placebo (18) in the Etanercept as Adjunctive Treatment for Acute Kawasaki Disease trial were included. All patients showed a persistent decrease in coronary artery size measurement: 23.3 versus 5.9% at the 6-month visit, 24 versus 13.1% at the 1-year visit, and 20.8 versus 19.3% at the ≥ 2-year visit for etanercept or placebo, respectively, with similar results for decrease in coronary artery z-scores. In a multivariate analysis, correcting for patients’ growth, a greater size reduction for patients on the etanercept arm versus placebo was proved significant for the 6-month (p = 0.005) and the 1-year visits (p = 0.019) with a similar end outcome at the ≥ 2-year visit.Discussion: Primary adjunctive therapy with etanercept for children with acute Kawasaki disease does not change the end outcome of coronary artery disease but may promote earlier resolution of artery dilation.Keywords
This publication has 28 references indexed in Scilit:
- Three Linked Vasculopathic Processes Characterize Kawasaki Disease: A Light and Transmission Electron Microscopic StudyPLOS ONE, 2012
- Efficacy and Limitation of Infliximab Treatment for Children with Kawasaki Disease Intractable to Intravenous Immunoglobulin Therapy: Report of an Open-label Case SeriesThe Journal of Rheumatology, 2012
- Etanercept as adjunctive treatment for acute kawasaki disease: Study design and rationaleAmerican Heart Journal, 2011
- When Children With Kawasaki Disease Grow UpJACC, 2009
- Fixed effects, random effects and GEE: What are the differences?Statistics in Medicine, 2008
- Coronary Artery Involvement in Children With Kawasaki DiseaseCirculation, 2007
- Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Statement for Health Professionals From the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart AssociationPediatrics, 2004
- Long term consequences of regressed coronary aneurysms after Kawasaki disease: vascular wall morphology and functionHeart, 2000
- Long-term Consequences of Kawasaki DiseaseCirculation, 1996
- Longitudinal data analysis using generalized linear modelsBiometrika, 1986